{"id":"W7116844250","doi":"10.1177/17588359251385410","title":"TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with <i>EGFR</i> -mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinib","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"William Osler Health System","funders":"Daiichi Sankyo Europe; National Cancer Institute; Eli Lilly Japan; Pfizer Japan; EMD Serono; Daiichi-Sankyo; Eli Lilly and Company; Ono Pharmaceutical; Sanofi; Apollomics; Yuhan; Taiho Pharmaceutical; Boehringer Ingelheim Japan; BeiGene; Chugai Pharmaceutical; Nihon Medi-Physics; Astellas Pharma; AstraZeneca; Novocure; Genomic Health; GlaxoSmithKline; Amgen; Pfizer; Les Laboratories Pierre Fabre; Bristol-Myers Squibb","keywords":"Osimertinib; Lung cancer; Chemotherapy; Disease; Randomized controlled trial; Phases of clinical research; Clinical trial; Lung disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002839948,0.002672359,0.003099109,0.0005678997,0.0004990936,0.00158671,0.001536345,0.002155773,0.006594178],"category_scores_gemma":[0.001652009,0.001055111,0.00238165,0.000500483,0.001951934,0.001598628,0.0006058621,0.003699856,0.00130717],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001432718,"about_ca_system_score_gemma":0.002391204,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001496404,"about_ca_topic_score_gemma":0.003104517,"domain_scores_codex":[0.9991854,0.0004077688,0.0000417261,0.0001583626,0.00005345622,0.0001533498],"domain_scores_gemma":[0.9986944,0.0002435339,0.0002644647,0.00009144488,0.0000681901,0.000637995],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9610846,0.02159801,0.0008868219,0.0003200845,0.0006267721,0.00004509429,0.00007768594,0.0005528823,0.004235573,0.0001539712,0.0006800517,0.009738416],"study_design_scores_gemma":[0.8787236,0.1189758,0.0008550956,0.00001278554,0.0002202097,0.00002877748,0.0000221332,0.0003622578,0.0003355842,0.00009475937,0.0003570349,0.00001195102],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9860405,0.001397779,0.0007406129,0.0005359303,0.000476132,0.007857452,0.001102934,0.0001485515,0.00170004],"genre_scores_gemma":[0.9787135,0.001575793,0.00230138,0.001604756,0.0003988457,0.009370824,0.001874206,0.00004485835,0.004115884],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006594178,"threshold_uncertainty_score":0,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01252559529437584,"score_gpt":0.3687785906845456,"score_spread":0.3562529953901697,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}